drugset / Trial / NCT06858254
Standard Optimization of Stem Cells in Parkinson's Disease and Atypical Parkinsonism
Phase 1/2
Not yet recruiting
60 enrolled
Apeiron Research Center
University of Colorado, Boulder · collab
RandomizedCrossoverSingle-blindTreatment
Summary
The purpose of this study is to measure outcomes using intranasal and intravenous autologous bone marrow mesenchymal stem cells (BM-MSCs) for Parkinson Disease (PD) and Parkinson's Plus (PPS) patients.
Timeline
- Start
- 2025-04-01
- Primary completion
- 2028-04
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous mesenchymal stem cells | Cell therapy | — | Intranasal |